The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer - PPAR

Barts and The London NHS Trust0 个研究点目标入组 49 人开始时间: 2006年3月31日最近更新: 2019年6月30日

试验速览

暂无简介。

•1.Androgen independent prostate cancer defined as rising PSA in the presence of MAB (withdrawal of peripheral anti-androgen 6 weeks prior to enrolment if previous response to addition of peripheral anti-androgen)
•2.ECOG performance status 0-2 (see appendix 1 for ECOG grading)
•3.Asymptomatic (lower urinary tract symptoms alone excluding haematuria is acceptable)
•4.Rising PSA
•5.Willing to undertake 6 weeks monitoring prior to starting treatment
•6.Males = 16 years of age
•7.Patients who have given written informed consent
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1.Receiving thiazolidenedione therapy or other oral hypoglycaemics
•2.Receiving fibrate therapy for hyperlipidemia
•3.Symptomatic disease requiring urgent palliation
•4.Life expectancy < 4 months
•5.Severe renal or hepatic dysfunction (Creatinine >200 µmol/l, Bilirubin >3xULN, ALT or AST >4xULN)
•6.Cardiac failure (new or treated)
•7.Concurrent participation in an interventional (drug) clinical trial
•8.Currently receiving treatment for Diabetes Mellitus (except diet controlled)
•9.Patient taking Diclofenac (may substitute an alternative non-steroidal anti-inflammatory drug prior to study entry)
•10.Unwilling or unable to provide written informed consent

发起方

Barts and The London NHS Trust